Advertisement

PentaVision

Optometric Management

Article

LEADING OFF: Also Notable

Optometric Management June 1, 2022 Vol 57, Issue June 2022 Page(s): 18, 20
  • ABB Optical Group is now an authorized distributor of Eyeris contact lenses. Eyeris currently offers a daily disposable soft contact lens with a prescription range of +6.00 D to -13.00 D (1/4 D steps from -4.75 to -7.50). For more information, visit https://info.abboptical.com/eyeris . Additionally, ABB Optical Group has unveiled a rebranding of its CONCISE Custom Soft contact lenses. The initial rebranding roll-out includes many new visual assets such as a revised logo and brand icon, a unique product tagline, “patient-friendly” product packaging, along with an array of practice support tools and educational resources.
  • Bausch + Lomb has become a publicly traded company and announced 35,000,000 common shares at a public-offering price of $18 per share. The company will trade on the New York Stock Exchange under the ticker symbol “BLCO.” Parent company Bausch Health and its subsidiaries will hold approximately 90% of the common shares of Bausch + Lomb. Additionally, Bausch + Lomb and Novaliq GmbH announced their perfluorohexyloctane (NOV03) drop to treat the signs and symptoms of dry eye disease linked with meibomian gland dysfunction met both primary endpoints of total corneal fluorescein staining in a multicenter, randomized, double-masked Phase 3 clinical trial. The study was comprised of 597 participants ages 18 years and older. Blurred vision, mostly mild and transient, was the only adverse event that occurred in a high proportion of subjects treated with NOV03 vs. control, according to the press release.
  • CooperVision and the World Council of Optometry committed to a second year of their myopia management partnership. The partnership plans to add a new series of clinical education resources and initiatives to its first-year milestones, which include a multilingual online learning resource for eye care professionals (ECPs), and a virtual event that more than 1,200 ECPs attended. See myopia.worldcouncilofoptometry.info/ . CooperVision has also launched two new digital tools. The MiSight “digital ecosystem” is designed to help ECPs help families learn about myopia control and contact lens hygiene beyond the exam room. More information can be found at MiSight.com . The ECP Viewpoints Online Success Center is a “one-stop digital education platform” intended to make contact lens information and training resources easily accessible to ECPs. Users can register to use the platform at successcenter.coopervision.com/login/index.php .
  • HOYA Vision Care shared the results of a six-year follow-up clinical study on its MiYOSMART spectacle lens that contains Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results demonstrate strong evidence of the lenses’ effectiveness in slowing myopia progression in children ages 8 to 13. Additionally, the follow-up study shows the myopia control effect is sustained over time for children wearing the lens.
  • The International Society for Contact Lens Research will hold its 21st symposium in Porto, Portugal, from August 21-26, 2022. The meeting will include the society’s global membership, industry partners, and keynote speakers. Attendance to the meeting is limited to society members, representatives from its corporate advisory board, and invited speakers, students, and researchers.
  • Johnson & Johnson Vision was recognized as the winner of Fast Company’s 2022 World Changing Ideas Awards in the Wellness category for the company’s ACUVUE Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen) contact lens. The World Changing Ideas Awards honor products, concepts, companies, policies, and designs that are pursuing innovation for the good of society and the planet, reports the press release. For more information on the drug-eluting contact lens, visit: acuvuetheravision.com .
  • Kala Pharmaceuticals, Inc. announced that its loteprednol etabonate ophthalmic suspension 0.25% (EYSUVIS) is now covered by Humana, named as a Preferred Brand on its Medicare formularies, effective June 1, 2022. The company also announced a direct-to-consumer campaign for EYSUVIS, a prescription therapy indicated specifically for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
  • Registration is now open for the Neuro-Optometric Rehabilitation Association (NORA) 32nd annual conference, held Sept. 8 to Sept. 11, 2022, at the Hyatt Regency Columbus, in Columbus, Ohio. Learn more at noravisionrehab.org/about-nora/annual-conferences/2022-annual-conference .
  • Ocuphire Pharma, Inc. announced positive results from the MIRA-4 pediatric safety trial regarding Nyxol for the reversal of pharmacologically induced mydriasis. Specifically, the results show that Nyxol’s efficacy and safety in those ages 3 to 11 was consistent with the findings of previous studies performed by the company, which enrolled those ages 12 to 17 and those age 18 and older. Ocuphire says it plans to submit a New Drug Application with the FDA in late 2022.
  • Prevent Blindness and Regeneron Pharmaceuticals, Inc. are partnering to increase education on the impact diabetes can have on vision and eye health through an expanded “Diabetes and the Eyes” program. Specifically, with the support of Regeneron, the program will now include a video series for both English and Spanish-language speakers, community-level health education and support, and refreshed materials, such as fact sheets and graphics. The program will also include a national awareness campaign where Prevent Blindness will utilize a variety of tactics to educate the public. Visit preventblindness.org .
  • RightEye has entered into a research collaboration agreement with the Massachusetts Institute of Technology (MIT) to study an oculomotor “signature” for Lyme disease. MIT researchers will be responsible for recruiting participants and conducting tests with control and experimental groups using the RightEye Vision System. The studies will examine those who have acute Lyme disease and chronic symptoms after. The study aims to determine whether oculomotor function can be used to generate a highly accurate, non-invasive, and sensitive biomarker for Lyme disease.
  • Tarsus Pharmaceuticals, Inc. announced that its lotilaner ophthalmic solution, 0.25% (TP-03) for the treatment of Demodex blepharitis met the primary endpoint (complete collarette cure) and all secondary endpoints (mite eradication and complete lid erythema cure), in a Phase 3 trial, along with a favorable safety profile. The randomized, controlled, double-masked trial was comprised of 412 adults who used TP-03 b.i.d. in each eye for six weeks. The only adverse events occurring at a rate of ≥1% in the TP-03 group were instillation site pain/burning/stinging (7.9%, n=16) and dry eye (1.5%, n=3). As a result, the company says it plans to submit a New Drug Application to the FDA in the second half of 2022.
  • Treehouse Eyes was named the winner of a Silver “Stevie” Award in the “Achievement in Growth” category and “Company of the Year - Health Products & Services – Small” category, from American Business Award. Nicknamed the Stevies for the Greek word meaning “crowned,” the awards will be presented at a ceremony at the Marriott Marquis Hotel, in New York, on Monday, June 13. Learn more about the Stevie Awards at StevieAwards.com .

What to Read Next